Selective PGE 2 suppression inhibits colon carcinogenesis and modifies local mucosal immunity

Cancer Prevention Research

Volumn 4, Issue 8, 2011, Pages 1198-1208

  Nakanishi, Masako ^a   Menoret, Antoine ^a   Tanaka, Takuji ^b   Miyamoto, Shingo ^a   Montrose, David C ^a   Vella, Anthony T ^a   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Cancer Research and Prevention   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; INDUCIBLE TERMINAL SYNTHASE; PROSTAGLANDIN E2; SYNTHETASE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CELL EXPANSION; CELL STIMULATION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DESCENDING COLON; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENE REPRESSION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPHOCYTE; MESENTERY LYMPH NODE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTICARCINOGENIC AGENTS; ARACHIDONIC ACID; AZOXYMETHANE; COLONIC NEOPLASMS; DINOPROSTONE; GENE DELETION; IMMUNITY, MUCOSAL; INTRAMOLECULAR OXIDOREDUCTASES; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSOMES;

EID: 80051480631     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0188     Document Type: Article

References (47)

1. Radmark O, Samuelsson B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. J Intern Med 2010;268:5-14.
2. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007;59:207-24. (Pubitemid 47481434)
3. Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW. mPGES-1 as a target for cancer suppression: a comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie 2010;92:660-4.
4. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 2008;68:3251-9.
5. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 1995;31A:1061-4.
6. Nambiar PR, Nakanishi M, Gupta R, Cheung E, Firouzi A, Ma XJ, et al. Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res 2004;64:6394-401. (Pubitemid 39297892)
7. Papanikolaou A, Wang QS, Papanikolaou D, Whiteley HE, Rosenberg DW. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 2000;21:1567-72. (Pubitemid 30601647)
8. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009;30:183-96.
9. Uematsu S, Matsumoto M, Takeda K, Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione- dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 2002; 168:5811-6. (Pubitemid 34556168)
10. Unkeless JC, Kaplan G, Plutner H, Cohn ZA. Fc-receptor variants of a mouse macrophage cell line. Proc Natl Acad SciUS A 1979;76:1400-4. (Pubitemid 9143748)
11. Menoret A, Myers LM, Lee SJ, Mittler RS, Rossi RJ, Vella AT. TGFbeta protein processing and activity through TCR triggering of primary CD8+ T regulatory cells. J Immunol 2006;177:6091-7. (Pubitemid 44628824)
12. Nambiar PR, Nakanishi M, Gupta RA, Cheung E, Firouzi A, Ma XJ, et al. Molecular signatures of high and low risk aberrant crypt foci in a mouse model of sporadic colon cancer. Dig Dis Week 2004:501.
13. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003;94: 965-73. (Pubitemid 37508979)
14. + mice. Cancer Prev Res 2010;3:1187-97.
15. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005;310:1504-10. (Pubitemid 41746348)
16. Guda K, Upender MB, Belinsky G, Flynn C, Nakanishi M, Marino JN, et al. Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene 2004;23:3813-21. (Pubitemid 38725694)
17. Maltzman T, Whittington J, Driggers L, Stephens J, Ahnen D. AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 1997;18:2435-9. (Pubitemid 28134660)
18. Takeda H, Sonoshita M, Oshima H, Sugihara K, Chulada PC, Langenbach R, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 2003;63:4872-7. (Pubitemid 37022619)
19. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane- associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275:32783-92.
20. Gudis K, Tatsuguchi A, Wada K, Futagami S, Nagata K, Hiratsuka T, et al. Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue. Lab Invest 2005;85:225-36. (Pubitemid 40208926)
21. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 2005;69 Suppl 1:28-32. (Pubitemid 41433539)
22. Shao J, Sheng H. Prostaglandin E2 induces the expression of IL- 1alpha in colon cancer cells. J Immunol 2007;178:4097-103. (Pubitemid 46492358)
23. + T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-20.
24. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302. (Pubitemid 30470312)
25. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506.
26. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
27. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67:4507-13. (Pubitemid 46815102)
28. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004;172:5986-93. (Pubitemid 38621199)
29. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29:781-8.
30. Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, et al. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res 2008;1:21-31.
31. Golijanin D, Tan JY, Kazior A, Cohen EG, Russo P, Dalbagni G, et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin Cancer Res 2004;10:1024-31. (Pubitemid 38198904)
32. Kamei D, Murakami M, Sasaki Y, Nakatani Y, Majima M, Ishikawa Y, et al. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem J 2009;425:361-71.
33. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971-6. (Pubitemid 34044615)
34. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996;270:G393-400.
35. Hara S, Kamei D, Sasaki Y, Tanemoto A, Nakatani Y, Murakami M. Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie 2010;92:651-9.
36. Montrose DC, Kadaveru K, Ilsley JN, Root SH, Rajan TV, Ramesh M, et al. cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci 2010;117:122-32.
37. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001;108:15-23. (Pubitemid 32634916)
38. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
39. Seddon B, Mason D. Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes. J Exp Med 1999;189:279-88. (Pubitemid 29063249)
40. + T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003;197:111-9.
41. + adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006;177:246-54.
42. Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005;175: 1483-90. (Pubitemid 41023048)
43. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjørnbeth BA, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008;57:813-21. (Pubitemid 351660125)
44. Monrad SU, Kojima F, Kapoor M, Kuan EL, Sarkar S, Randolph GJ, et al. Genetic deletion of mPGES-1 abolishes PGE2 production in murine dendritic cells and alters the cytokine profile, but does not affect maturation or migration. Prostaglandins Leukot Essent Fatty Acids 2011;84:113-21.
45. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
46. Waldner MJ, Neurath MF. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 2009;31:249-56.
47. Mladenova D, Daniel JJ, Dahlstrom JE, Bean E, Gupta R, Pickford R, et al. The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 2011;60: 350-60.